Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 47.52 million compared to USD 41.04 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.291 USD | -0.34% |
|
+6.99% | -94.45% |
Jul. 01 | Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Completeness Index | CI |
1st Jan change | Capi. | |
---|---|---|
-94.45% | 17.74M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |